Novo Nordisk A/S Common Stock (NVO)

Total Costs & Expenses

kr 187.33B

TTM · Period ending: · DKK

NVO logo

NVO Total Costs & Expenses

Latest reportedkr 187.33B DKK
NVO TTM Total Costs & Expenses · DKK (kr 4.19B → kr 187.33B)
High-resolution chart · PNG

NVO total costs & expenses history

Trailing twelve months (TTM) · DKK. Each value covers four complete reported quarters.

Novo Nordisk A/S Common Stock Total Costs & Expenses — Trailing twelve months (TTM) (DKK)
Period endingTotal Costs & Expenses (DKK)
187,334,000,000
179,315,000,000
181,406,000,000
182,944,000,000
169,139,000,000
167,857,000,000
162,064,000,000
152,215,000,000
146,544,000,000
134,830,000,000
129,687,000,000
121,595,000,000
115,159,000,000
107,621,000,000
102,145,000,000
95,839,000,000
90,830,000,000
86,218,000,000
82,156,000,000
78,417,000,000
76,163,000,000
74,069,000,000
72,820,000,000
72,404,000,000
71,643,000,000
72,059,000,000
69,538,000,000
67,943,000,000
66,534,000,000
65,153,000,000
64,583,000,000
63,579,000,000
62,200,000,000
62,249,000,000
62,729,000,000
63,150,000,000
63,697,000,000
63,407,000,000
63,348,000,000
62,733,000,000
62,428,000,000
62,043,000,000
58,483,000,000
56,160,000,000
55,028,000,000
53,347,000,000
54,314,000,000
53,230,000,000
52,069,000,000
51,968,000,000
52,079,000,000
51,125,000,000
50,587,000,000
49,607,000,000
48,552,000,000
47,201,000,000
46,142,000,000
45,063,000,000
43,972,000,000
43,713,000,000
43,251,000,000
42,868,000,000
41,885,000,000
39,948,000,000
38,191,000,000
36,749,000,000
36,145,000,000
35,612,458,000
34,831,458,000
34,185,797,000
33,282,797,000
33,846,512,500
33,743,493,500
33,234,353,500
32,939,028,500
31,444,899,000
30,707,858,000
30,050,181,000
29,627,766,000
28,729,535,000
28,129,835,000
26,964,203,000
25,650,000,000
24,333,701,000
23,500,725,000
22,850,891,000
22,118,728,000
21,385,003,000
20,812,430,000
20,404,666,000
20,155,434,000
21,405,688,000
22,774,665,000
23,177,853,000
24,426,535,000
24,247,657,000
24,454,101,000
24,921,297,000
24,247,334,000
19,910,110,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.